ERS/Industry joint session supported by GSK and Janssen
Aims : COVID 19 has demonstrated the importance of infection diseases in terms of morbidity and mortality, especially for people with chronic respiratory diseases. Vaccination is the most important preventive measure against this. Many vaccinations are recommended in our guidelines worldwide. Even so, vaccination rates are still low. The aim of this symposium is to present the current status in the development of various vaccines and thus move the importance of vaccination more into the focus of care for respiratory patients.
SARSCorona2 as the new, influenza as the classic and pertussis infectious disease as the forgotten will be presented in this symposium. The current standing of vaccination and the development of vaccines for this will be reportedd. Strategies to increase vaccination rates will be discussed.
Target audience :
Adult pulmonologist/Clinician, Physician in Pulmonary Training, Respiratory critical care physician, Clinical researcher